Treatment involves prevention of infection with antimicrobial prophylaxis. Vigilant monitoring for infection is required, as patients may have few symptoms despite active serious infection. Because of the heterogeneity and the seriousness of infection, prompt therapeutic measures are indicated. Early consultation with physicians experienced in the care of Chronic granulomatous disease (CGD) is recommended.
Active infections
Procedures to aid in identification of the infecting organism, such as surgical biopsy of infected sites or bronchoalveolar lavage, are recommended before treatment if available. Immediate treatment of any infection should be undertaken in consultation with specialists in immunology and infectious diseases, as infections require aggressive and prolonged therapy. Initial treatment includes broad intravenous coverage of Staphylococcus aureus and gram-negative pathogens, such as Serratia marcescens and Burkholderia cepacia. Early broad antifungal coverage is often needed as well, specifically for Aspergillus species; voriconazole, posaconazole, or liposomal amphotericin are the agents of choice; itraconazole is an alternative option.[58]Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002 Aug 8;347(6):408-15.
https://www.nejm.org/doi/full/10.1056/NEJMoa020191#t=article
http://www.ncbi.nlm.nih.gov/pubmed/12167683?tool=bestpractice.com
[59]Antachopoulos C, Walsh TJ, Roilides E. Fungal infections in primary immunodeficiencies. Eur J Pediatr. 2007 Nov;166(11):1099-117.
http://www.ncbi.nlm.nih.gov/pubmed/17551753?tool=bestpractice.com
[60]Seger RA. Modern management of chronic granulomatous disease. Br J Haematol. 2008 Feb;140(3):255-66.
http://www.ncbi.nlm.nih.gov/pubmed/18217895?tool=bestpractice.com
Once the organism is identified, directed therapy may be initiated.
Granulocyte transfusions may be administered as a "last resort" for life-threatening infections.[61]Bielorai B, Toren A, Wolach B, et al. Successful treatment of invasive aspergillosis in chronic granulomatous disease by granulocyte transfusion followed by peripheral blood stem cell transplantation. Bone Marrow Transplant. 2000 Nov;26(9):1025-8.
https://www.nature.com/bmt/journal/v26/n9/full/1702651a.html
http://www.ncbi.nlm.nih.gov/pubmed/11100285?tool=bestpractice.com
[62]Yomtovian R, Abramson J, Quie P, et al. Granulocyte transfusion therapy in chronic granulomatous disease. Report of a patient and review of the literature. Transfusion. 1981 Nov-Dec;21(6):739-43.
http://www.ncbi.nlm.nih.gov/pubmed/7314224?tool=bestpractice.com
[63]Ozsahin H, von Planta M, Muller I, et al. Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mobilized granulocytes, and liposomal amphotericin B. Blood. 1998 Oct 15;92(8):2719-24.
https://bloodjournal.hematologylibrary.org/cgi/content/full/92/8/2719
http://www.ncbi.nlm.nih.gov/pubmed/9763555?tool=bestpractice.com
[64]Ikinciogullari A, Dogu F, Solaz N, et al. Granulocyte transfusions in children with chronic granulomatous disease and invasive aspergillosis. Ther Apher Dial. 2005 Apr;9(2):137-41.
http://www.ncbi.nlm.nih.gov/pubmed/15828925?tool=bestpractice.com
[65]Stroncek DF, Leonard K, Eiber G, et al. Alloimmunization after granulocyte transfusions. Transfusion. 1996 Nov-Dec;36(11-12):1009-15.
http://www.ncbi.nlm.nih.gov/pubmed/8937413?tool=bestpractice.com
[50]Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015 Nov;136(5):1186-205.e1-78.
https://www.doi.org/10.1016/j.jaci.2015.04.049
http://www.ncbi.nlm.nih.gov/pubmed/26371839?tool=bestpractice.com
The short-term benefits of providing functional granulocytes should be weighed against the risk from exposure to foreign antigens (e.g., HLA antigens). Alloimmunization is associated with risk of transfusion reactions and may compromise future hematopoietic stem cell transplantation.[65]Stroncek DF, Leonard K, Eiber G, et al. Alloimmunization after granulocyte transfusions. Transfusion. 1996 Nov-Dec;36(11-12):1009-15.
http://www.ncbi.nlm.nih.gov/pubmed/8937413?tool=bestpractice.com
The use of interferon gamma in the treatment of infections in CGD patients remains poorly studied and controversial, although some experts support its use in severely ill patients in the hope of providing benefit.[41]Fischer A, Segal AW, Seger R, et al. The management of chronic granulomatous disease. Eur J Pediatr. 1993 Nov;152(11):896-9.
http://www.ncbi.nlm.nih.gov/pubmed/8276018?tool=bestpractice.com
Surgical or radiologic drainage of infected tissue may be required for life-threatening infections.
Hepatic abscesses
Hepatic abscesses are treated with antibiotics in conjunction with corticosteroids, although they may require surgical drainage or excision and are frequently associated with complications.[66]Leiding JW, Freeman AF, Marciano BE, et al. Corticosteroid therapy for liver abscess in chronic granulomatous disease. Clin Infect Dis. 2012 Mar 1;54(5):694-700.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3275758
http://www.ncbi.nlm.nih.gov/pubmed/22157170?tool=bestpractice.com
[67]Straughan DM, McLoughlin KC, Mullinax JE, et al. The changing paradigm of management of liver abscesses in chronic granulomatous disease. Clin Infect Dis. 2018 Apr 17;66(9):1427-34.
http://www.ncbi.nlm.nih.gov/pubmed/29145578?tool=bestpractice.com
Definitive surgical excision and drainage should be considered in patients not responding to antibiotic and corticosteroid therapy.[50]Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015 Nov;136(5):1186-205.e1-78.
https://www.doi.org/10.1016/j.jaci.2015.04.049
http://www.ncbi.nlm.nih.gov/pubmed/26371839?tool=bestpractice.com
S aureus is typically the etiology.[12]Lublin M, Bartlett DL, Danforth DN, et al. Hepatic abscess in patients with chronic granulomatous disease. Ann Surg. 2002 Mar;235(3):383-91.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1422444/?tool=pubmed
http://www.ncbi.nlm.nih.gov/pubmed/11882760?tool=bestpractice.com
Percutaneous drainage may be helpful.
The use of normal donor granulocytes injected into lesions has been reported, as well as systemic granulocyte infusions and interferon gamma administration.[68]Lekstrom-Himes JA, Holland SM, DeCarlo ES, et al. Treatment with intralesional granulocyte instillations and interferon-gamma for a patient with chronic granulomatous disease and multiple hepatic abscesses. Clin Infect Dis. 1994 Oct;19(4):770-3.
http://www.ncbi.nlm.nih.gov/pubmed/7803648?tool=bestpractice.com
Systemic antibiotic and antifungal treatment is recommended postoperatively in those undergoing surgery.
Gastrointestinal or genitourinary sequelae
Enterocolitis, gastrointestinal obstruction, or genitourinary obstruction secondary to granuloma formation are possible complications. If enterocolitis is infectious in nature, then antibiotics are warranted. However, in CGD, patients often suffer from Crohn-like bowel disease, and the mainstay of therapy is immune suppression, most often with sulfasalazine (or an alternative aminosalicylate) for mild disease or corticosteroids for severe disease and flares. Other more potent immunosuppressive agents may also be used, although caution should be exercised with anti-TNF therapy due to a high rate of complications.[69]Uzel G, Orange JS, Poliak N, et al. Complications of tumor necrosis factor-α blockade in chronic granulomatous disease-related colitis. Clin Infect Dis. 2010 Dec 15;51(12):1429-34.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3106244
http://www.ncbi.nlm.nih.gov/pubmed/21058909?tool=bestpractice.com
Most obstructions of hollow viscera can be managed with corticosteroids, although surgery is indicated for nonresolving obstruction or severe fistulae.[6]Marciano BE, Rosenzweig SD, Kleiner DE, et al. Gastrointestinal involvement in chronic granulomatous disease. Pediatrics. 2004 Aug;114(2):462-8.
http://www.ncbi.nlm.nih.gov/pubmed/15286231?tool=bestpractice.com
[8]Huang A, Abbasakoor F, Vaizey CJ. Gastrointestinal manifestations of chronic granulomatous disease. Colorectal Dis. 2004 Aug;2(8):690-5.
http://www.ncbi.nlm.nih.gov/pubmed/16970572?tool=bestpractice.com
[11]Walther MM, Malech H, Berman A, et al. The urological manifestations of chronic granulomatous disease. J Urol. 1992 May;147(5):1314-8.
http://www.ncbi.nlm.nih.gov/pubmed/1569675?tool=bestpractice.com
Prophylactic treatment
Prophylactic treatment is an essential component of CGD management and consists of antimicrobial prophylaxis with or without interferon gamma. Trimethoprim/sulfamethoxazole decreases the incidence of bacterial infection in patients with CGD, with varying effects on the incidence of fungal infection.[15]Mouy R, Veber F, Blanche S, et al. Long-term itraconazole prophylaxis against Aspergillus infections in thirty-two patients with chronic granulomatous disease. J Pediatr. 1994 Dec;125(6 Pt 1):998-1003.
http://www.ncbi.nlm.nih.gov/pubmed/7996377?tool=bestpractice.com
[16]Martire B, Rondelli R, Soresina A, et al. Clinical features, long-term follow-up and outcome of a large cohort of patients with chronic granulomatous disease: an Italian multicenter study. Clin Immunol. 2008 Feb;126(2):155-64.
http://www.ncbi.nlm.nih.gov/pubmed/18037347?tool=bestpractice.com
[70]Margolis DM, Melnick DA, Alling DW, et al. Trimethoprim-sulfamethoxazole prophylaxis in the management of chronic granulomatous disease. J Infect Dis. 1990 Sep;162(3):723-6.
http://www.ncbi.nlm.nih.gov/pubmed/2117627?tool=bestpractice.com
Patients who have an allergy to trimethoprim/sulfamethoxazole may be treated with alternative antibiotics. An additional agent may be required to cover methicillin-resistant S aureus if prevalent.
Antifungal prophylaxis with itraconazole has become the standard of care for patients with CGD, and is shown to decrease the incidence of fungal infection.[71]Gallin JI, Alling DW, Malech HL, et al. Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med. 2003 Jun 12;348(24):2416-22.
https://www.nejm.org/doi/full/10.1056/NEJMoa021931#t=article
http://www.ncbi.nlm.nih.gov/pubmed/12802027?tool=bestpractice.com
Aspergillus infections have been the most common cause of death in patients with CGD, although this is changing with widespread use of antifungal prophylaxis.[3]Winkelstein JA, Marino MC, Johnston RB Jr., et al. Chronic granulomatous disease: report on a national registry of 368 patients. Medicine (Baltimore). 2000 May;79(3):155-69.
http://www.ncbi.nlm.nih.gov/pubmed/10844935?tool=bestpractice.com
[16]Martire B, Rondelli R, Soresina A, et al. Clinical features, long-term follow-up and outcome of a large cohort of patients with chronic granulomatous disease: an Italian multicenter study. Clin Immunol. 2008 Feb;126(2):155-64.
http://www.ncbi.nlm.nih.gov/pubmed/18037347?tool=bestpractice.com
[13]Hasui M. Chronic granulomatous disease in Japan: incidence and natural history. The Study Group of Phagocyte Disorders of Japan. Pediatr Int. 1999 Oct;41(5):589-93.
http://www.ncbi.nlm.nih.gov/pubmed/10530081?tool=bestpractice.com
If itraconazole is not tolerated, choose an alternative antifungal prophylactic medication that is effective against Aspergillus species. Voriconazole is an oral alternative, but it carries the risk of reversible liver damage, photosensitivity, and cutaneous malignancy.[58]Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002 Aug 8;347(6):408-15.
https://www.nejm.org/doi/full/10.1056/NEJMoa020191#t=article
http://www.ncbi.nlm.nih.gov/pubmed/12167683?tool=bestpractice.com
[59]Antachopoulos C, Walsh TJ, Roilides E. Fungal infections in primary immunodeficiencies. Eur J Pediatr. 2007 Nov;166(11):1099-117.
http://www.ncbi.nlm.nih.gov/pubmed/17551753?tool=bestpractice.com
[72]Williams K, Mansh M, Chin-Hong P, et al. Voriconazole-associated cutaneous malignancy: a literature review on photocarcinogenesis in organ transplant recipients. Clin Infect Dis. 2014 Apr;58(7):997-1002.
http://www.ncbi.nlm.nih.gov/pubmed/24363331?tool=bestpractice.com
Posaconazole has been used for salvage therapy in patients, although this restricts treatment options for breakthrough infection.[73]Segal BH, Barnhart LA, Anderson VL, et al. Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. Clin Infect Dis. 2005 Jun 1;40(11):1684-8.
https://cid.oxfordjournals.org/content/40/11/1684.full
http://www.ncbi.nlm.nih.gov/pubmed/15889369?tool=bestpractice.com
Serum drug levels may be required in patients on azole antifungals.
Interferon gamma decreases the incidence of infection, although study results are conflicting.[30]Foster CB, Lehrnbecher T, Mol F, et al. Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease. J Clin Invest. 1998 Dec 15;102(12):2146-55.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC509169/pdf/1022146.pdf
http://www.ncbi.nlm.nih.gov/pubmed/9854050?tool=bestpractice.com
[74]The International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med. 1991 Feb 21;324(8):509-16.
http://www.ncbi.nlm.nih.gov/pubmed/1846940?tool=bestpractice.com
[75]Weening RS, Leitz GJ, Seger RA. Recombinant human interferon-gamma in patients with chronic granulomatous disease - European follow up study. Eur J Pediatr. 1995 Apr;154(4):295-8.
http://www.ncbi.nlm.nih.gov/pubmed/7607280?tool=bestpractice.com
[76]Marciano BE, Wesley R, De Carlo ES, et al. Long-term interferon-gamma therapy for patients with chronic granulomatous disease. Clin Infect Dis. 2004 Sep 1;39(5):692-9.
https://cid.oxfordjournals.org/content/39/5/692.long
http://www.ncbi.nlm.nih.gov/pubmed/15356785?tool=bestpractice.com
[77]Goldblatt D. Current treatment options for chronic granulomatous disease. Expert Opin Pharmacother. 2002 Jul;3(7):857-63.
http://www.ncbi.nlm.nih.gov/pubmed/12083986?tool=bestpractice.com
Additionally, adverse effects limit usage. The routine use of interferon gamma is highly variable even among specialists. Fever is a common adverse effect associated with interferon treatment. However, the occurrence of fever in a patient with CGD always warrants medical evaluation.
Allogeneic stem cell transplantation
Allogeneic stem cell transplantation is a curative procedure, although it carries its own risks of mortality and morbidity particularly if undertaken later in life. Overall survival is greater than 80%, with the majority of surviving patients achieving cure, particularly if an HLA-matched donor is available.[78]Hasegawa D, Fukushima M, Hosokawa Y, et al. Successful treatment of chronic granulomatous disease with fludarabine-based reduced-intensity conditioning and unrelated bone marrow transplantation. Int J Hematol. 2008 Jan;87(1):88-90.
http://www.ncbi.nlm.nih.gov/pubmed/18224420?tool=bestpractice.com
[79]Sastry J, Kakakios A, Tugwell H, et al. Allogeneic bone marrow transplantation with reduced intensity conditioning for chronic granulomatous disease complicated by invasive Aspergillus infection. Pediatr Blood Cancer. 2006 Sep;47(3):327-9.
http://www.ncbi.nlm.nih.gov/pubmed/16628555?tool=bestpractice.com
[80]Parikh SH, Szabolcs P, Prasad VK, et al. Correction of chronic granulomatous disease after second unrelated-donor umbilical cord transplantation. Pediatr Blood Cancer. 2007 Dec;49(7):982-4.
http://www.ncbi.nlm.nih.gov/pubmed/17941061?tool=bestpractice.com
[81]Seger RA, Gungor T, Belohradsky BH, et al. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000. Blood. 2002 Dec 15;100(13):4344-50.
https://bloodjournal.hematologylibrary.org/cgi/content/full/100/13/4344
http://www.ncbi.nlm.nih.gov/pubmed/12393596?tool=bestpractice.com
[82]Del Giudice I, Iori AP, Mengarelli A, et al. Allogeneic stem cell transplant from HLA-identical sibling for chronic granulomatous disease and review of the literature. Ann Hematol. 2003 Mar;82(3):189-92.
http://www.ncbi.nlm.nih.gov/pubmed/12634956?tool=bestpractice.com
[83]Kansoy S, Kutukculer N, Aksoylar S, et al. Successful bone marrow transplantation in an 8-month-old patient with chronic granulomatous disease. Turk J Pediatr. 2006 Jul-Sep;48(3):253-5.
http://www.ncbi.nlm.nih.gov/pubmed/17172071?tool=bestpractice.com
[84]Soncini E, Slatter MA, Jones LB, et al. Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth. Br J Haematol. 2009 Apr;145(1):73-83.
http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2009.07614.x/full
http://www.ncbi.nlm.nih.gov/pubmed/19222467?tool=bestpractice.com
Recent advances in critical care support and in carefully applied conditioning regimens are improving the mortality and morbidity for transplant patients.
Transplantation should be considered as soon as diagnosis is made if a matched sibling donor is available.[50]Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015 Nov;136(5):1186-205.e1-78.
https://www.doi.org/10.1016/j.jaci.2015.04.049
http://www.ncbi.nlm.nih.gov/pubmed/26371839?tool=bestpractice.com
Additionally, matched unrelated (including cord blood) donors should be considered appropriate sources for stem cells in children. In adults, very careful consideration must be given to the potential risks and benefits of stem cell transplantation.
Stem cell transplantation should be undertaken in medical centers experienced in transplantation for primary immunodeficiency disorders. Stem cell transplantation has been successfully used to rescue patients with refractory infection, although risks are increased.